TSX open
Loading markets…

Advertisement

Stocks

Why Telo Genomics Corp stock is plummeting today

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:TELO.V

Follow TELO

Photos provided by Pexels

Telo Genomics Corp faces a significant setback as its stock drops over 11% in a single trading session.

In a disappointing turn of events, Telo Genomics Corp (TELO.V) saw its stock price fall by 11.11%, closing at CA$0.04. This decline raises concerns among investors about the company's direction and future prospects, especially considering its recent operational expansions and leadership changes.

Advertisement

Telo Genomics Corp

TELO.V

Full stock page →

TELO.V

Telo Genomics Corp

Source:WealthAwesomeWealthAwesome
↑ $0.01 (11.11%)
120 day period
$0.04$0.05$0.07Mar 4Jun 1Oct 6

Market cap

$5.02M

52W high

$0.10

52W low

$0.03

1W change

+42.86%

Beta

0.11

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on TELO's historical volatility

HistoricalForecast68%95%
C$0.00C$0.08C$0.15C$0.23C$0.30C$0.37TodayApr 16Jun 22Oct 6Nov 18Jan 1Feb 13

30-Day Vol

180.7%

Annualized

90-Day Vol

142.9%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$0.04

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.05C$0.03 – C$0.09
60 trading daysC$0.04C$0.02 – C$0.11
90 trading daysC$0.04C$0.01 – C$0.12

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors should keep a close eye on Telo Genomics Corp's performance and be cautious about potential volatility, particularly since there hasn't been any recent positive news to counter this downturn.

Telo Genomics Corp's stock tumbles 11.11% in one day

The stock's decline reflects broader investor sentiment and worries about the company's ability to achieve sustainable growth.

Bull case

Telo Genomics is expanding its operations and has recently moved to a larger facility in Toronto. This could set the stage for future growth if the company can effectively leverage these developments.

Bear case

The sharp drop in stock price, especially without any accompanying news, indicates investor concerns about the company's fundamentals. This is particularly troubling given its low market cap of CA$4.5 million and ongoing lack of profitability.

Advertisement

Market Reaction

The 11.11% drop in Telo Genomics' stock price shows a negative reaction from the market. Investors might be reevaluating the company's growth potential after its recent operational changes, like relocating its clinical laboratories to a new facility in Toronto. Despite these expansions, the absence of positive news or financial indicators likely contributed to the stock's decline.

Future Outlook

As Telo Genomics navigates this downturn, investors will be watching closely for updates on its operational performance or strategic initiatives. The company's recent leadership changes and facility expansions could lay the groundwork for recovery, but without clear signs of profitability or growth, uncertainty will likely remain. For more detailed insights, visit our Telo Genomics stock page.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: July 7, 2026
Last Updated: September 25, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement